This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Acute disseminated encephalomyelitis (ADEM) is a demyelinating disorder of the CNS that seems to be immune mediated. [1,2] It is usually preceded by a viral syndrome and presents with acute neurologic signs. [1] ADEM is usually monophasic, but recurrent episodes may occur. [3] When ADEM is recurrent, the distinction from MS becomes difficult. [2] Corticosteroids are commonly used in ADEM and are thought to shorten the duration of the neurologic symptoms. [4] We report on the use of intravenous gammaglobulin (IVIG) therapy for ADEM after failure of corticosteroids.
Case report.
An 8-year-old previously healthy boy developed headaches and fever 2 weeks before admission to Packard Children's Hospital at Stanford. He was admitted to a community hospital. Vital signs were normal except for a temperature of 100.9 degrees F. There were no signs of meningeal irritation. LP showed 23 WBC/mm3 (34% polymorphonuclear cells, 45% lymphocytes, 21% monocytes), 0 RBC/mm3, with a protein of 23 mg/dL and a glucose of 63 mg/dL. MRI showed prominent leptomeningeal enhancement but no other lesions. He was diagnosed with viral meningitis and treated with IV acylovir for 9 days. Headaches worsened despite analgesics, and he was transferred to the Children's Hospital. On examination, he was awake but in significant distress from a severe headache. His speech and comprehension were normal. Vital signs were normal except for a temperature of 100.7 degrees F. The general examination was unremarkable. There were several beats of ankle clonus, and the plantar responses were extensor bilaterally. The …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
